Sarepta Therapeutics, Inc. 1Q23 Earnings Conference Call
Forward Looking Statements

Tuesday, May 2, 2023 – 4:30 p.m. Eastern Time

In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this conference call. Any statements made by Sarepta that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, financial performance and projections, business plans, market opportunities, priorities, research and development programs, and the potential benefits of our product candidates; our full-year net product revenue guidance for our PMO therapies of greater than $925; the potentially transformative benefits of SRP-9001; our belief that we meet the criteria for accelerated approval for SRP-9001, including our belief that the SRP-9001 dystrophin protein, in the amounts expressed by the therapy, is reasonably likely to predict clinical benefit; our expectations and beliefs related to the advisory committee for SRP-9001, including the primary areas of discussion related to: the conclusion that SRP-9001 dystrophin protein, at the levels expressed by the therapy, is reasonably likely to predict clinical benefit, the totality of evidence of natural history, preclinical data, biomarker results and functional results from our clinical trials, the risk/benefit analysis associated with the administration of SRP-9001 for the treatment of ambulatory patients with Duchenne in the context of accelerated approval and an assessment of the ability to bring to conclusion EMBARK, our proposed post marketing confirmatory trial to support the accelerated approval of SRP-9001, in the event accelerated approval is granted; our goal to alter the course of Duchenne with our one-time gene therapy SRP-9001; the potential benefits of our AAV of choice, rh74, and our promoter MHCK7; our belief that our VOYAGENE study will give us insights into a broader LGMD patient population; our goal to ensure that our gene therapy for Duchenne is accessible to patients who need it and engaging with payors to achieve such goal; and expected timelines, plans and milestones, including ensuring we are prepared to successfully launch SRP-9001 in the event accelerated approval is granted, expanding the SRP-9001 label to broader populations based on additional studies, advancing our LGMD portfolio across a variety of subtypes and providing updates in the months ahead, completing enrollment of VOYAGENE in the second half of this year and beginning our phase 3 study using commercially representative process material later in the year, commencing a systemic pilot study for SRP-6004, announcing data for our MOMENTUM trial in the back half of 2023, completing enrollment of our MISSION study this year, and our regulatory action date for SRP-9001 of May 29, 2023.

These forward-looking statements involve risks and uncertainties, many of which are beyond our control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to meet expectations with respect to sales of our products or attain the anticipated net revenues, profitability or positive cash-flow from operations; we may not be able to comply with all FDA post-approval commitments and requirements with respect to our products in a timely manner or at all; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business, as well as the development of our product candidates and our financial and contractual obligations; our dependence on certain manufacturers to produce our products and product candidates, including any inability on our part to accurately anticipate product demand and timely secure manufacturing capacity to meet product demand, may impair the availability of product to successfully support various programs; our data for SRP-5051, SRP-9001, the LGMD programs, including SRP-9003, and/or other programs may not be sufficient for obtaining regulatory approval; success in preclinical and clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; the commencement and completion of our clinical trials and announcement of results may be delayed or prevented for a number of reasons, including, among others, denial by the regulatory agencies of permission to proceed with our clinical trials, or placement of a clinical trial on hold, challenges in identifying, recruiting, enrolling and retaining patients to participate in clinical trials and inadequate quantity or quality of supplies of a product candidate or other materials necessary to conduct clinical trials; different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results, and even if we believe the data collected from clinical trials of our product candidates are positive, these data may not be sufficient to support approval by the FDA or other global regulatory authorities; if the actual number of patients living with the diseases we aim to treat is smaller than estimated, our revenue and ability to achieve profitability may be adversely affected; we may not be able to execute on our business plans, including meeting our expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing our product candidates to market, for various reasons, many of which may be outside of our control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates, and the ongoing COVID-19 pandemic; and those risks identified under the heading "Risk Factors" in our most recent Annual Report on Form 10-K for the year ended December 31, 2022 and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.